Vitasora Health Completes Final Tranche of A$11m Capital Raising

Vitasora Health ( (AU:VHL) ) has shared an update.

Vitasora Health Limited has completed the final tranche of an A$11 million capital raising, issuing 81,499,999 fully paid ordinary shares as part of the funding round first detailed in 2025. The company confirmed the shares were issued without a prospectus under applicable Australian securities law and stated it remains compliant with continuous disclosure and financial reporting obligations, with no excluded information relevant to investors’ assessment of its securities.

The capital completion bolsters Vitasora Health’s financial position as it scales its remote patient monitoring, chronic care management services, and wheezo medical device across the U.S. connected care market. By reinforcing its balance sheet while maintaining regulatory compliance, the company aims to strengthen its role in chronic disease management and support further integration of its cost-saving, data-driven solutions into healthcare providers’ existing systems.

The most recent analyst rating on (AU:VHL) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Vitasora Health stock, see the AU:VHL Stock Forecast page.

More about Vitasora Health

Vitasora Health Limited is a Melbourne-headquartered digital healthcare company focused on connected care solutions for the U.S. market. It delivers remote patient monitoring and chronic care management services through a turnkey model for healthcare providers, supported by advanced R&D such as its exclusive remote wheeze detection technology. The company also developed wheezo, an FDA-approved Class II wheeze-detection device that integrates with RPM programs and a companion app, enabling data-driven management of major chronic conditions.

Average Trading Volume: 1,197,560

Technical Sentiment Signal: Sell

Current Market Cap: A$44.6M

See more insights into VHL stock on TipRanks’ Stock Analysis page.